Saxagliptin: Addressing Unmet Needs in Type 2 Diabetes  

Oleh:

Tong, Peter CY

Jenis: Article from Bulletin/Magazine - ilmiah internasional
Dalam koleksi: Medical Progress vol. 37 no. 11 (Nov. 2010), page 551-556.
Topik: Type 2 Diabetes

Ketersediaan

Perpustakaan FK Nomor Panggil: M36.K.2010.02 Non-tandon: 1 (dapat dipinjam: 0) Tandon: tidak ada

Lihat Detail Induk

Isi artikel

Optimal glycaemic control is difficult to achieve in the progression of type 2 diabetes. Currently available therapies are limeted by inadequate postprandial glucose control, hypoglycaemia, and weight gain. However, the availability of a new class of oral antidiabetic drugs that targets the incretin hormones brings about new promise to the treatment of type 2 diabetes. This article elaborates on recent trial data featuring a new dipeptidyl peptidase-4 inhibitor, saxagliptin, and its physiologic management of HbA1c, fasting plasma glucose and postprandial glucose levels.

Opini Anda

Klik untuk menuliskan opini Anda tentang koleksi ini!

Kembali